Atrium Therapeutics, Inc.

RNAReported to SECin USCIK 0002093101Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 8. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 8
Form 4 lines at Atrium Therapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Younis HusamChief Scientific OfficerAdministrative$100,38311,216 sharesSep 22, 2026Younis HusamChief Scientific Officer$100,383Admin · Sep 22Administrative11,216Sep 22, 2026
Hughes Steven GeorgeChief Medical OfficerAdministrative$192,05821,459 sharesSep 22, 2026Hughes Steven GeorgeChief Medical Officer$192,058Admin · Sep 22Administrative21,459Sep 22, 2026
Flanagan W. Michael—Administrative$204,16722,812 sharesSep 22, 2026Flanagan W. Michael$204,167Admin · Sep 22Administrative22,812Sep 22, 2026
Boyce Sarah—Administrative$1,131,441126,418 sharesSep 22, 2026Boyce Sarah$1,131,441Admin · Sep 22Administrative126,418Sep 22, 2026
Kenney StephanieSee RemarksAdministrative$21,2562,375 sharesSep 22, 2026Kenney StephanieSee Remarks$21,256Admin · Sep 22Administrative2,375Sep 22, 2026